Humanigen, Inc. (HGEN)
Chart Events
Performance Outlook
| Previous Close | 0.3711 |
| Open | 0.3710 |
| Bid | 0.3790 x 800 |
| Ask | 0.3798 x 2200 |
| Day's Range | 0.3658 - 0.3820 |
| 52 Week Range | 0.3500 - 18.2200 |
| Volume | |
| Avg. Volume | 7,857,867 |
| Market Cap | 26.841M |
| Beta (5Y Monthly) | -1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1140 |
| Earnings Date | Nov 10, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HGEN
Related Research
- Humanigen, Inc.Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.RatingFair ValueEconomic Moat23 hours agoArgus Research
- Newsfile
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a
- American City Business Journals
Martin Shkreli's onetime company loses 80% of value as Covid drug trial fails
The company, whose history includes pharma bad-boy Martin Shkreli and a trip into Chapter 11 bankruptcy, had hoped the National Institutes of Health-sponsored study would help it win FDA emergency use authorization.
- TipRanks
Humanigen Stock: Why It Crashed and Where It’s Headed
Covid-19 opened up plenty of opportunities for smaller pharma companies to make their mark, by developing either vaccines or treatments. But it’s no easy task getting a product approved, and many have been unable to get their candidates across the finish line. The latest victim in the space appears to be Humanigen (HGEN). Shares took a proper thrashing in Wednesday’s session, after the company disclosed that its experimental antibody Lenzilumab failed to make the grade as a treatment for hospita
